DENTSPLY SIRONA Inc. XRAY topped second-quarter 2026 earnings and revenue expectations while keeping its full-year outlook intact. The results showed better cash generation and selected margin gains, but they did not mark a broad recovery in dental demand.
The post-earnings question is whether those improvements can outweigh falling sales, tariff pressure and continued weakness in equipment, orthodontics and implants. Wellspect Healthcare remained the clearest growth offset.
XRAY’s Q2 Beat Came With Lower Revenue
Adjusted earnings of 52 cents per share beat the Zacks Consensus Estimate of 36 cents by 44.4%. Revenues of $898 million topped the consensus estimate by 1.6%.
That beat came despite revenues falling 4.1% year over year as reported and 6.3% at constant currency. Weakness across three dental segments and the absence of Byte kept the quarter from signaling a broad sales recovery.
XRAY’s Wellspect Unit Provided the Bright Spot
Wellspect Healthcare revenues rose 7.1% to $86 million, supported by new product launches. Connected Technology Solutions fell 1.5%, Essential Dental Solutions declined 2.7% and Orthodontic and Implant Solutions dropped 13.2%.
The wider dental market is mixed. Align Technology, Inc. ALGN reported 8.2% growth in second-quarter clear-aligner revenues, but its Imaging Systems and computer-aided design and manufacturing services revenues fell 10.8%. Envista Holdings Corporation NVST reported 5.0% core sales growth, showing that industry demand is uneven rather than uniformly weak.
XRAY’s Margins Show a Mixed but Better Picture
Adjusted gross margin improved 50 basis points to 56.4%, while adjusted EBITDA margin increased 20 basis points to 21.3%. Tariff refunds helped both measures.
Adjusted operating margin, however, contracted 240 basis points to 15.8%. Lower volumes, unfavorable mix, tariff costs and higher selling, general and administrative expenses and increased research and development spending continued to limit operating leverage.
XRAY’s Cash Flow Improves as Liquidity Tightens
Second-quarter free cash flow increased to $55 million from $16 million a year earlier. First-half operating cash flow rose to $139 million from $55 million, aided by tariff refunds and better management of inventory and accounts payable.
Cash and cash equivalents stood at $239 million at June 30, down from $326 million at Dec. 31, 2025. The net debt-to-EBITDA ratio was 3.2, keeping balance-sheet flexibility and debt reduction important to the turnaround.
XRAY Keeps 2026 Guidance Despite Uneven Demand
Dentsply Sirona maintained its 2026 net sales outlook of $3.5 billion to $3.6 billion and adjusted earnings guidance of $1.40-$1.50 per share. Benefits from tariff refunds are excluded from the adjusted earnings outlook.
Maintaining guidance gives investors a clear second-half benchmark. A more durable recovery still depends on better equipment demand, stabilization in SureSmile and implants and improved conversion from the company’s expanded dealer network and commercial investments.
XRAY’s Scores Keep the Post-Earnings View Balanced
The quarter supports a measured view rather than a clean turnaround call. Better cash flow and some margin improvement are constructive, but sales contraction, tariffs and execution risk remain meaningful.
XRAY currently carries a Zacks Rank #3 (Hold), with a Value Score of A, Growth Score of B, Momentum Score of F and VGM Score of B. The Value Score of A, Growth Score of B and VGM Score of B point to relatively favorable value, growth and blended characteristics, while the Momentum Score of F signals weak near-term momentum. Combined with a Hold rank, the setup remains balanced. While Envista Holdings sports a Zacks Rank #1 (Strong Buy), Align Technology carries a Zacks Rank of 3.You can see the complete list of today’s Zacks #1 Rank stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
Envista Holdings Corporation (NVST): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
